FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322769305> ?p ?o ?g. }

• W4322769305 endingPage "01" @default.
• W4322769305 startingPage "P5" @default.
• W4322769305 abstract "Abstract Background: Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a non-invasive surrogate source of tumor material to investigate tumor characteristics in real-time. However, the only FDA-cleared CTC assay is limited to the enumeration of surface marker-defined epithelial cells and not designed for further characterization of the CTCs identified. The Parsortix® PC1 system is a semi-automated microfluidic device capable of capturing and harvesting CTCs from peripheral blood based on cell size and deformability, making it cell-surface marker agnostic. Here, we demonstrate that the Parsortix® PC1 system enables the enrichment and capture of CTCs from the blood of patients with metastatic breast cancer (MBC) and their interrogation using evaluation techniques commonly available in clinical laboratories. Methods: As part of a multicenter clinical trial (NCT03427450), peripheral blood samples from 216 patients with MBC and 205 healthy volunteers (HVs) were prospectively collected at four different clinical sites located throughout the United States. Each subject provided two separate blood samples collected into K2EDTA Vacutainer® tubes to be processed using the Parsortix® PC1 system on the same day. The cells harvested from one of the blood samples collected from each subject by the Parsortix® PC1 system were deposited onto cytology slides using a cytocentrifugation method and stained with Wright-Giemsa reagents using an automated stainer. The stained slides were subjected to cytopathological evaluation by a board-certified pathologist to enumerate CTCs. As proof of principle, cells harvested from the second blood sample were evaluated using one of three additional techniques: molecular profiling by qRT-PCR, RNA sequencing, or cytogenetic analysis of HER2 amplification by FISH. Results: Cytologic examination identified one or more cells as a CTC in 48.5% (95% CI of 41.5 – 55.4%) of the 194 patients with MBC and 9.9% (95% CI of 6.4 – 14.9%) of the 192 HVs. The results from the qRT-PCR evaluation (102 HVs and 74 MBC patients) showed differential expression of cancer-related genes (KRT19, EPCAM, and TWIST1) in the patients with MBC compared to the HVs. Results from the RNA sequencing (53 HVs and 16 MBC patients) showed differential expression of several genes involved in the Kegg Cancer Pathway in the patients with MBC compared to the HVs. The results from the HER2 FISH evaluation (38 HVs and 101 MBC patients) showed that while the majority of the CTC identified had normal HER2/CEP17 ratios, detection of HER2 amplification was possible. Conclusions: The Parsortix PC1 system is capable of capturing and harvesting CTCs from the peripheral blood of patients with MBC. Harvested cells can be evaluated using standard orthogonal methodologies such as gene expression and FISH to identify and characterize CTCs. Based in part on the above results, the FDA granted a De Novo classification request (DEN200062) for the Parsortix PC1 device in May of 2022. Citation Format: Evan Cohen, Gitanjali Jayachandran, Richard Moore, Massimo Cristofanilli, Julie E. Lang, Joseph Khoury, Michael F. Press, Heather McBride, Kyu Kwang Kim, Negar Khazan, Qiang Zhang, Youbin Zhang, Roberta Guzman, Michael C. Miller, James Reuben, Naoto T. Ueno. A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System in support of FDA clearance [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-06-01." @default.
• W4322769305 created "2023-03-03" @default.
• W4322769305 creator A5012804198 @default.
• W4322769305 creator A5023601563 @default.
• W4322769305 creator A5024359940 @default.
• W4322769305 creator A5032987754 @default.
• W4322769305 creator A5037000390 @default.
• W4322769305 creator A5038333329 @default.
• W4322769305 creator A5038881654 @default.
• W4322769305 creator A5039837606 @default.
• W4322769305 creator A5046839542 @default.
• W4322769305 creator A5052236281 @default.
• W4322769305 creator A5057968678 @default.
• W4322769305 creator A5058453547 @default.
• W4322769305 creator A5069614323 @default.
• W4322769305 creator A5088814426 @default.
• W4322769305 creator A5088881526 @default.
• W4322769305 creator A5089217769 @default.
• W4322769305 date "2023-03-01" @default.
• W4322769305 modified "2023-09-26" @default.
• W4322769305 title "Abstract P5-06-01: A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System in support of FDA clearance" @default.
• W4322769305 doi "https://doi.org/10.1158/1538-7445.sabcs22-p5-06-01" @default.
• W4322769305 hasPublicationYear "2023" @default.
• W4322769305 type Work @default.
• W4322769305 citedByCount "0" @default.
• W4322769305 crossrefType "journal-article" @default.
• W4322769305 hasAuthorship W4322769305A5012804198 @default.
• W4322769305 hasAuthorship W4322769305A5023601563 @default.
• W4322769305 hasAuthorship W4322769305A5024359940 @default.
• W4322769305 hasAuthorship W4322769305A5032987754 @default.
• W4322769305 hasAuthorship W4322769305A5037000390 @default.
• W4322769305 hasAuthorship W4322769305A5038333329 @default.
• W4322769305 hasAuthorship W4322769305A5038881654 @default.
• W4322769305 hasAuthorship W4322769305A5039837606 @default.
• W4322769305 hasAuthorship W4322769305A5046839542 @default.
• W4322769305 hasAuthorship W4322769305A5052236281 @default.
• W4322769305 hasAuthorship W4322769305A5057968678 @default.
• W4322769305 hasAuthorship W4322769305A5058453547 @default.
• W4322769305 hasAuthorship W4322769305A5069614323 @default.
• W4322769305 hasAuthorship W4322769305A5088814426 @default.
• W4322769305 hasAuthorship W4322769305A5088881526 @default.
• W4322769305 hasAuthorship W4322769305A5089217769 @default.
• W4322769305 hasConcept C121608353 @default.
• W4322769305 hasConcept C126322002 @default.
• W4322769305 hasConcept C142724271 @default.
• W4322769305 hasConcept C143998085 @default.
• W4322769305 hasConcept C2775930923 @default.
• W4322769305 hasConcept C2779013556 @default.
• W4322769305 hasConcept C530470458 @default.
• W4322769305 hasConcept C61238886 @default.
• W4322769305 hasConcept C71924100 @default.
• W4322769305 hasConceptScore W4322769305C121608353 @default.
• W4322769305 hasConceptScore W4322769305C126322002 @default.
• W4322769305 hasConceptScore W4322769305C142724271 @default.
• W4322769305 hasConceptScore W4322769305C143998085 @default.
• W4322769305 hasConceptScore W4322769305C2775930923 @default.
• W4322769305 hasConceptScore W4322769305C2779013556 @default.
• W4322769305 hasConceptScore W4322769305C530470458 @default.
• W4322769305 hasConceptScore W4322769305C61238886 @default.
• W4322769305 hasConceptScore W4322769305C71924100 @default.
• W4322769305 hasIssue "5_Supplement" @default.
• W4322769305 hasLocation W43227693051 @default.
• W4322769305 hasOpenAccess W4322769305 @default.
• W4322769305 hasPrimaryLocation W43227693051 @default.
• W4322769305 hasRelatedWork W144521535 @default.
• W4322769305 hasRelatedWork W1918973407 @default.
• W4322769305 hasRelatedWork W2006173697 @default.
• W4322769305 hasRelatedWork W2395906155 @default.
• W4322769305 hasRelatedWork W2411890706 @default.
• W4322769305 hasRelatedWork W2806005235 @default.
• W4322769305 hasRelatedWork W2909057618 @default.
• W4322769305 hasRelatedWork W2979892935 @default.
• W4322769305 hasRelatedWork W3181412252 @default.
• W4322769305 hasRelatedWork W2006001742 @default.
• W4322769305 hasVolume "83" @default.
• W4322769305 isParatext "false" @default.
• W4322769305 isRetracted "false" @default.
• W4322769305 workType "article" @default.